Search | GSK

ViiV Healthcare presents GEMINI 1 & 2 studies through Week 96 showing 2-drug regimen of dolutegravir plus lamivudine continues to demonstrate high efficacy rates and no cases of treatment emergent resistance

Media

First published: 24 July 2019

ViiV Healthcare presents GEMINI 1 & 2 studies through Week 96 showing 2-drug regimen of dolutegravir plus lamivudine continues to demonstrate high efficacy rates and no cases of treatment emergent ...

https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-gemini-1-2-studies-through-week-96-showing-2-drug-regimen-of-dolutegravir-plus-lamivudine-continues-to-demonstrate-high-efficacy-rates/

ARIA study shows superior efficacy of Triumeq® for treatment-naïve women living with HIV

Media

First published: 18 July 2016

ViiV Healthcare today presented 48-week data from the phase IIIb, open-label, international, multi-centre ARIA study which showed superior efficacy for Triumeq® (dolutegravir/abacavir/lamivudine) c...

https://www.gsk.com/en-gb/media/press-releases/aria-study-shows-superior-efficacy-of-triumeq-for-treatment-naïve-women-living-with-hiv/

New Phase IIIb/IV data show switching to once-daily Triumeq® maintains HIV viral suppression

Media

First published: 23 September 2015

ViiV Healthcare today announced 24-week data from the Phase IIIb/IV STRIIVING study

https://www.gsk.com/en-gb/media/press-releases/new-phase-iiibiv-data-show-switching-to-once-daily-triumeq-maintains-hiv-viral-suppression/

GSK's Promacta® (eltrombopag) receives FDA approval of an additional indication

Media

First published: 26 August 2014

New first-in-class treatment option for this previously treated SAA patient population

https://www.gsk.com/en-gb/media/press-releases/gsks-promacta-eltrombopag-receives-fda-approval-of-an-additional-indication/

ViiV Healthcare announces new collaboration with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1

Media

First published: 12 June 2014

ViiV Healthcare today announced that they have entered into an agreement with Janssen R&D Ireland Ltd (Janssen) for the development and commercialisation of a single-tablet combining dolutegravir (...

https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-new-collaboration-with-janssen-to-investigate-single-tablet-regimen-for-maintenance-treatment-of-hiv-1/

ViiV Healthcare presents phase III data

Media

First published: 22 July 2014

An investigational two drug-regimen of maraviroc dosed once daily, combined with darunavir/ritonavir (DRV/r) showed inferior efficacy compared to emtricitabine/tenofovir (FTC/TDF) with DRV/r.

https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-phase-iii-data/

GlaxoSmithKline update: A (H1N1) influenza vaccine development

Media

First published: 14 May 2009

GSK has received orders from several governments aiming to stockpile a new candidate A (H1N1) adjuvanted influenza vaccine as a precautionary measure

https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-update-a-h1n1-influenza-vaccine-development/

ViiV Healthcare announces detailed positive phase III results for investigational two-drug regimen of dolutegravir and rilpivirine for HIV treatment

Media

First published: 13 February 2017

Headline results were announced in December 2016 and detailed study results are being presented at the annual Conference

https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-detailed-positive-phase-iii-results-for-investigational-two-drug-regimen-of-dolutegravir-and-rilpivirine-for-hiv-treatment/

ViiV Healthcare submits regulatory applications for the first HIV maintenance regimen comprising only two medicines

Media

First published: 01 June 2017

ViiV Healthcare submits regulatory applications for the first HIV maintenance regimen comprising only two medicines

https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-submits-regulatory-applications-for-the-first-hiv-maintenance-regimen-comprising-only-two-medicines/

ViiV Healthcare receives EU marketing authorisation for Juluca (dolutegravir/rilpivirine), the first 2-drug regimen, once-daily, single-pill for the treatment of HIV

Media

First published: 21 May 2018

Juluca maintains viral suppression with two drugs in the smallest single pill regimen

https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-eu-marketing-authorisation-for-juluca-dolutegravirrilpivirine-the-first-2-drug-regimen-once-daily-single-pill-for-the-treatment-of-hiv/